Adaptimmune Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADAP research report →
About the company
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets.
- CEO
- Adrian G. Rawcliffe
- IPO
- 2015
- Employees
- 506
- HQ
- Abingdon, GB
Price Chart
- Market Cap
- $75.16M
- P/E
- -0.13
- P/S
- 0.49
- P/B
- -0.15
- EV/EBITDA
- -0.48
- Div Yield
- 0.00%
- Gross Margin
- 83.88%
- Op Margin
- -362.66%
- Net Margin
- -371.74%
- ROE
- 143.79%
- ROIC
- -86.24%
- Revenue
- $178.03M · 195.34%
- Net Income
- $-70,814,000 · 37.81%
- EPS
- $-0.28 · 50.42%
- Op Income
- $-68,760,000
- FCF YoY
- 47.91%
- 52W High
- $0.86
- 52W Low
- $0.02
- 50D MA
- $0.10
- 200D MA
- $0.26
- Beta
- 2.49
- Avg Volume
- 110.64M
Get TickerSpark's AI analysis on ADAP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ADAP coverage
Recent articles, reports, and earnings notes.
No research on ADAP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADAP report →Similar companies
Peers in the same neighborhood.